Deep Space Biology has developed Yotta, an AI-driven platform that processes multi-omic data from living entities, significantly reducing research time from years to minutes. By leveraging 25 years of microgravity research, Yotta enhances drug discovery and enables researchers to formulate more informed hypotheses for complex diseases affecting human health.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of analyzing multi-omic data from biological samples are time-consuming, often taking years to process and interpret the complex interactions within living systems. This slow pace hinders drug discovery and the formulation of informed hypotheses for understanding and treating complex diseases.
Solution
Deep Space Biology offers Yotta, an AI-driven platform designed to accelerate the analysis of multi-omic data derived from living entities. By leveraging insights gained from 25 years of microgravity research, Yotta significantly reduces the time required for data processing and interpretation, enabling researchers to formulate more targeted hypotheses. The platform facilitates a deeper understanding of complex diseases, ultimately enhancing drug discovery efforts and improving human health outcomes.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and the study of complex diseases.
Features
- AI-powered analysis of multi-omic data, including genomics, proteomics, and metabolomics
- Integration of data from microgravity research to enhance biological insights
- Rapid data processing capabilities, reducing analysis time from years to minutes
- Tools for formulating informed hypotheses about complex diseases
- User-friendly interface for data visualization and interpretation